Clinical trial
BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00024024 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00024024 |
|---|---|
| Title | BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma |
| Official title | A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | rebimastat |
| Enrollment | 59 |
| Start date | Aug 1, 2001 |
| Primary completion | Aug 1, 2003 |
| First posted | Aug 5, 2003 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: